江西三鑫医疗科技股份有限公司 2022 年第一季度报告全文 证券代码：300453 证券简称：三鑫医疗 公告编号：2022-023 江西三鑫医疗科技股份有限公司 2022年第一季度报告 (二)非经常性损益项目和金额 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 321,497,637.25 | 246,148,032.60 | 30.61% | | 归属于上市公司股东的净利润（元） | 47,447,45 ...

Financial Performance - The company's operating revenue for 2021 was ¥1,164,288,763.57, representing a 23.81% increase compared to ¥940,385,589.06 in 2020[24]. - The net profit attributable to shareholders for 2021 was ¥155,910,663.53, a 34.84% increase from ¥115,624,846.75 in 2020[24]. - The net profit after deducting non-recurring gains and losses was ¥145,190,265.25, up 43.68% from ¥101,050,763.98 in 2020[24]. - The company's cash flow from operating activities for 2021 was ¥329,716,957.18, a 20.82% increase from ¥272,895,487.24 in 2020[24]. - The total assets at the end of 2021 were ¥1,406,039,522.12, reflecting a 12.96% increase from ¥1,244,754,307.25 at the end of 2020[24]. - The net assets attributable to shareholders at the end of 2021 were ¥905,506,389.18, a 15.32% increase from ¥785,198,391.69 at the end of 2020[24]. - The company achieved operating revenue of CNY 1,164.29 million, a year-on-year increase of 23.81%[90]. - Net profit attributable to shareholders reached CNY 155.91 million, up 34.84% compared to the previous year[82]. - The total revenue for 2021 was approximately CNY 1.28 billion, representing an increase of 18.22% compared to CNY 1.08 billion in 2020[105]. Dividend Distribution - The company plans to distribute a cash dividend of 1.50 RMB per 10 shares to all shareholders, based on a total of 394,027,500 shares[9]. - The company distributed a cash dividend of RMB 2.00 per 10 shares, totaling RMB 52,537,000, and issued 1.5 bonus shares per 10 shares, along with a capital increase of 3.5 shares per 10 shares, increasing the total share capital to 394,027,500 shares[161]. - The total distributable profit for the year was RMB 416,784,890.37, with the cash dividend accounting for 100% of the profit distribution[163]. - The company's cash dividend policy complies with the company's articles of association and provides clear standards and procedures for distribution[162]. Market Position and Strategy - The company is focused on expanding its market presence and developing new products and technologies to enhance competitiveness[6]. - The company has established several wholly-owned and controlling subsidiaries to enhance its operational capabilities and market reach[17]. - The company has been recognized as a leading enterprise in the blood purification industry, providing a full range of products including dialysis machines and related consumables[40]. - The company aims to expand its market presence through strategic initiatives and product innovation in the medical device sector[47]. - The company has a strong brand presence in the blood purification market, with its products gaining recognition and trust among customers[81]. - The company plans to continue expanding its market share in blood purification products and enhance its product structure through new developments[85]. Research and Development - The company has a strong R&D team and capabilities, having established multiple research centers and contributed to the formulation of 2 national standards and 8 industry standards[78]. - The company’s R&D investment for 2021 was CNY 61.19 million, accounting for 5.26% of total revenue, representing a year-on-year increase of 30.29%[102]. - The number of R&D personnel increased to 247 in 2021, up 9.78% from 225 in 2020, with R&D personnel now making up 13.15% of the total workforce[102]. - The company is focused on reducing the economic burden on patients by promoting domestic alternatives to imported products[102]. - The company aims to enhance its core competitiveness and market expansion capabilities through the development of new products[102]. Regulatory and Compliance - The company operates in a highly regulated medical device industry, which is subject to strict national policies and quality control standards[6][7]. - The company has received various certifications, including CE and FDA510(k), ensuring compliance with international quality standards[79]. - The company has implemented a transparent performance evaluation and incentive mechanism for senior management[130]. - The company has established and optimized internal control systems in accordance with the latest regulations, ensuring effective governance and decision-making processes[171]. - There were no significant internal control deficiencies identified during the reporting period, with all financial and non-financial reporting controls deemed effective[172]. Corporate Governance - The company has established a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and management team[124]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[126]. - The company maintains independence from its controlling shareholders in terms of business, personnel, assets, and finance[132]. - The company actively engages with shareholders through various communication channels to ensure their rights are protected[125]. - The company’s board has been proactive in enhancing the operational standards and protecting the rights of minority shareholders[152]. Social Responsibility and Sustainability - The company has actively engaged in social responsibility initiatives, emphasizing employee welfare and contributions to health advancements[181]. - The company has implemented measures to reduce carbon emissions, including the use of clean energy sources and optimizing production locations to minimize transportation emissions[180]. - The company was recognized as a "2021 Occupational Health Demonstration Enterprise" in Nanchang, reflecting its commitment to workplace safety and health[179]. - The company actively creates job opportunities to support rural employment and talent development[184]. - The company has implemented a procurement management system to maintain a win-win situation with suppliers[183]. Product Development and Innovation - The company has continuously optimized its product structure, transitioning from traditional infusion to a comprehensive range of medical devices across six major segments[33]. - The company has established a complete industrial chain from blood purification consumables to equipment, positioning itself as a leader in the industry[35]. - The company reported a significant focus on the development of single-use sterile injection devices, which are designed to minimize injection pain for insulin administration[57]. - The introduction of a closed intravenous catheter system allows for a needle-free connection, reducing the workload for healthcare professionals[59]. - The company is expanding its product line to include light-protective infusion devices, which are essential for administering light-sensitive medications[63].

江西三鑫医疗科技股份有限公司 2021 年第三季度报告 证券代码：300453 证券简称：三鑫医疗 公告编号：2021-058 江西三鑫医疗科技股份有限公司 2021年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 否 | | 本报告期 | 本报告期比上年 | 年初至报告期 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 同期增减 | 末 | 比上年同期增减 | | 营业收入（元） | 317,476,887.58 | 29.40% | 826,470,119.67 | 21.18% | | 归属于上市公司股东的净利润（元） | 43,331,185.29 | 15.33% | 114,500,391.96 | 39.54% | | 归属于上 ...

江西三鑫医疗科技股份有限公司 2021 年半年度报告全文 江西三鑫医疗科技股份有限公司 2021 年半年度报告 2021-041 2021 年 07 月 1 江西三鑫医疗科技股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人彭义兴、主管会计工作负责人邹蓓廷及会计机构负责人(会计主 管人员)舒南妹声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成本公司 对任何投资者及相关人士的实质承诺，投资者及相关人士均应当对此保持足够 的风险认识，并且应当理解计划、预测与承诺之间的差异。 （1）国家政策风险 医疗器械行业既是国家重点鼓励和扶持的产业，同时也是受国家监管程度 较高的行业，包括行业准入、生产条件、质量标准等。若国家有关监管政策发 生重大变化，将有可能导致整个行业的竞争格局出现新的变化，从而对本公司 的生产经营带来新挑战。 （ ...

江西三鑫医疗科技股份有限公司 2021 年第一季度报告全文 江西三鑫医疗科技股份有限公司 2021 年第一季度报告 2021-025 2021 年 04 月 1 江西三鑫医疗科技股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人彭义兴、主管会计工作负责人邹蓓廷及会计机构负责人(会计主 管人员)舒南妹声明：保证季度报告中财务报表的真实、准确、完整。 2 江西三鑫医疗科技股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 246,148,032.60 | 172,344,526.82 | 42.82% | | 归属于上市公司股东的净利润（元） | 34,044 ...

江西三鑫医疗科技股份有限公司 2020 年年度报告全文 江西三鑫医疗科技股份有限公司 2020 年年度报告 2021-011 2021 年 03 月 江西三鑫医疗科技股份有限公司 2020 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司负责人彭义兴、主管会计工作负责人邹蓓廷及会计机构负责人(会计主 管人员)舒南妹声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成本公司 对任何投资者及相关人士的实质承诺，投资者及相关人士均应当对此保持足够 的风险认识，并且应当理解计划、预测与承诺之间的差异。 （1）国家政策风险 随着公司并购业务的开展并进入新的业务领域，公司可能面临业务整合、 提高整体运营效率等方面的挑战和风险。 公司经本次董事会审议通过的利润分配预案为：以 262,685,000 股为基数， 向全体股东每 10 股派发现金红利 2 元（含税），送红股 ...

江西三鑫医疗科技股份有限公司 2020 年第三季度报告全文 江西三鑫医疗科技股份有限公司 2020 年第三季度报告 2020-092 2020 年 10 月 1 江西三鑫医疗科技股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人彭义兴、主管会计工作负责人乐珍荣及会计机构负责人(会计主 管人员)舒南妹声明：保证季度报告中财务报表的真实、准确、完整。 2 江西三鑫医疗科技股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 1,181,717,112.26 | 1,145,700,357.46 | | 3.14% | | 归属于上市公司股东的净 ...

证券代码：300453 证券简称：三鑫医疗 公告编号：2020-061 江西三鑫医疗科技股份有限公司 关于参加江西辖区上市公司 2020年投资者集体接待日活动的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 为便于广大投资者更深入全面地了解公司情况、发展战略、经营状况、融资计 划、可持续发展等投资者所关心的问题，江西三鑫医疗科技股份有限公司（以下简 称"公司"）定于2020年7月17日下午15:00-17:00参加由江西省上市公司协会联合 深圳市全景网络有限公司举办的主题为"以高质量沟通，促高质量发展"江西上市 公司2020年投资者集体接待日活动。现将有关事项公告如下： 本次集体接待日网上交流网址：投资者可以登录http://rs.p5w.net 进入专区 页面参与交流。 出席本次集体接待日的人员有：公司董事、总经理毛志平先生，副总经理、财 务总监乐珍荣先生、董事会秘书刘明先生。 欢迎广大投资者积极参与。 特此公告 江西三鑫医疗科技股份有限公司董事会 2020年7月15日 ...

Financial Performance - Total revenue for Q1 2020 was CNY 172,344,526.82, representing a 27.45% increase compared to CNY 135,229,590.90 in the same period last year[7]. - Net profit attributable to shareholders was CNY 12,143,542.89, a significant increase of 141.73% from CNY 5,023,567.97 year-on-year[7]. - Net profit excluding non-recurring items reached CNY 9,640,940.93, up 136.56% from CNY 4,075,536.06 in the previous year[7]. - Basic earnings per share increased to CNY 0.05, a 150.00% rise compared to CNY 0.02 in the previous year[7]. - The company achieved a total operating revenue of 172.34 million yuan, an increase of 27.45% compared to the same period last year[23]. - The net profit for Q1 2020 reached CNY 13,663,166.99, compared to CNY 4,960,715.02 in the same period last year, representing a growth of approximately 175%[50]. - The total profit for Q1 2020 was CNY 16,489,282.87, significantly higher than CNY 5,733,908.61 in the prior year[49]. - The operating profit for Q1 2020 was CNY 18,522,743.59, compared to CNY 5,893,610.16 in the same quarter last year[49]. Cash Flow and Assets - Net cash flow from operating activities improved to CNY 22,537,655.83, a turnaround from a negative cash flow of CNY -28,265,579.28 in the same quarter last year, marking a 179.74% increase[7]. - Cash inflows from operating activities totaled CNY 231,595,387.86, a substantial increase from CNY 123,001,149.68 in the previous period[56]. - The company’s cash and cash equivalents decreased by 54.82% to ¥50,107,043.60, mainly due to the purchase of financial products[22]. - The total cash and cash equivalents at the end of Q1 2020 were CNY 37,979,679.35, down from CNY 104,220,982.10 at the beginning of the period, reflecting a decrease of 63.6%[58]. - Total assets at the end of the reporting period were CNY 1,146,295,322.53, a slight increase of 0.05% from CNY 1,145,700,357.46 at the end of the previous year[7]. - The company’s total equity increased from CNY 676,026,592.04 to CNY 718,024,096.97, indicating growth in shareholder value[68]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,365[11]. - The largest shareholder, Peng Yixing, holds 24.79% of the shares, with 65,115,920 shares, of which 48,836,940 are pledged[11]. - The company reported that shareholders in management positions will not transfer more than 25% of their total shares held annually during their tenure and for six months after leaving[30]. - The controlling shareholders pledged not to reduce their holdings in the company for three years following the stock market listing[30]. - The company has committed to ensuring that the information disclosure documents related to the stock incentive plan do not contain false records, misleading statements, or significant omissions[29]. Expenses and Investments - Sales expenses increased by 40.25% to ¥24,245,746.94 due to intensified market development efforts for blood purification products and increased sales of dialysis solutions[22]. - R&D expenses rose by 79.27% to ¥3,913,570.35, reflecting increased investment in research and development during the reporting period[22]. - Financial expenses increased by 31.91% to ¥1,143,549.04 due to higher interest expenses from increased borrowings[22]. - The company reported a significant increase in operating profit, leading to a 265.51% rise in income tax expenses to ¥2,826,115.88[22]. Restricted Shares and Incentives - The company has a commitment to lock 75% of shares for directors during their term, affecting multiple shareholders[15]. - The company plans to gradually release restricted shares based on performance evaluations over the next two years[15]. - The total number of restricted stocks granted across all executives amounts to 1,056,000, indicating a significant commitment to performance-based incentives[16][17]. - The company emphasizes the importance of aligning executive compensation with long-term performance metrics[16][17]. Risks and Compliance - The company faces risks related to national policy changes, quality control, and market shrinkage of traditional infusion products[25][26]. - Management risks may arise from business integration and expansion into new areas, which the company is prepared to address[27]. - The company has maintained compliance with all commitments made by its shareholders and management regarding share transfers and reductions[30].